Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diamyd + vitamin D + ibuprofen
- Development stage
- Unknown
- Lead developer
- Diamyd Medical
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Oral
01
Overview
This combination therapy, evaluated in the DIABGAD-1 trial, is designed to preserve residual insulin secretion in patients with recent-onset type 1 diabetes. It consists of Diamyd (recombinant human GAD65 formulated with aluminum hydroxide), oral vitamin D, and oral ibuprofen. Diamyd acts as an antigen-specific immunotherapy to induce immune tolerance toward the GAD65 autoantigen, which is a target of autoimmune destruction in type 1 diabetes. Vitamin D and ibuprofen are included to provide additional immunomodulatory and anti-inflammatory effects, potentially enhancing the efficacy of the GAD-alum vaccine in protecting pancreatic beta cells.
- Brand names
- Diamyd
- Other names
- GAD-alum + vitamin D + ibuprofenrhGAD65 + vitamin D + ibuprofen
02
Targets
GAD2 (Glutamic Acid Decarboxylase 65)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on Diamyd + vitamin D + ibuprofen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diamyd + vitamin D + ibuprofen.